| Title: | A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries |
| Authors: | Moon, Suerie Jambert, Elodie Childs, Michelle von Schoen-Angerer, Tido |
| Affiliation: | Harvard Kennedy School and School of Public Health, Boston, USA; Médecins Sans Frontières, Campaign for Access to Essential Medicines, Geneva, Switzerland |
| Citation: | Globalization and Health 2011; 7:39 |
| Publisher: | BioMed Central |
| Journal: | Globalization and Health |
| Issue Date: | 12-Oct-2011 |
| URI: | http://hdl.handle.net/10144/220355 |
| DOI: | 10.1186/1744-8603-7-39 |
| PubMed ID: | 21992405 |
| Additional Links: | http://www.globalizationandhealth.com/content/7/1/39 |
| Abstract: | Background: Tiered pricing - the concept of selling drugs and vaccines in developing countries at prices
systematically lower than in industrialized countries - has received widespread support from industry, policymakers,
civil society, and academics as a way to improve access to medicines for the poor. We carried out case studies
based on a review of international drug price developments for antiretrovirals, artemisinin combination therapies,
drug-resistant tuberculosis medicines, liposomal amphotericin B (for visceral leishmaniasis), and pneumococcal
vaccines.
Discussion: We found several critical shortcomings to tiered pricing: it is inferior to competition for achieving the
lowest sustainable prices; it often involves arbitrary divisions between markets and/or countries, which can lead to
very high prices for middle-income markets; and it leaves a disproportionate amount of decision-making power in
the hands of sellers vis-à-vis consumers. In many developing countries, resources are often stretched so tight that
affordability can only be approached by selling medicines at or near the cost of production. Policies that “de-link”
the financing of R&D from the price of medicines merit further attention, since they can reward innovation while
exploiting robust competition in production to generate the lowest sustainable prices. However, in special cases -
such as when market volumes are very small or multi-source production capacity is lacking - tiered pricing may
offer the only practical option to meet short-term needs for access to a product. In such cases, steps should be
taken to ensure affordability and availability in the longer-term.
Summary: To ensure access to medicines for populations in need, alternate strategies should be explored that
harness the power of competition, avoid arbitrary market segmentation, and/or recognize government
responsibilities. Competition should generally be the default option for achieving affordability, as it has proven
superior to tiered pricing for reliably achieving the lowest sustainable prices. |
| Type: | Article |
| Language: | en |
| MeSH: | Developing Countries Health Policy |
| ISSN: | 1744-8603 |
| Rights: | Archived with thanks to Globalization and Health's Open Access policy |
| Appears in topics: | Health Politics
|
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.